| Bioactivity | Avadomide (CC 122) is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity and induces apoptosis of diffuse large B-cell lymphoma (DLBCL) cell lines. Avadomide exhibits potent antitumor and immunomodulatory activities[1][2]. | ||||||||||||
| Invitro | Avadomide inhibits proliferation and induces apoptosis in ABC and GCB DLBCL. In DLBCL cell lines, Avadomide-induced degradation or short hairpin RNA-mediated knockdown of Aiolos and Ikaros correlates with increased transcription of IFN-stimulated genes independent of IFN-α, -β, and -γ production and/or secretion and results in apoptosis in both activated B-cell (ABC) and germinal center B-cell DLBCL.[1] | ||||||||||||
| Name | Avadomide | ||||||||||||
| CAS | 1015474-32-4 | ||||||||||||
| Formula | C14H14N4O3 | ||||||||||||
| Molar Mass | 286.29 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Avadomide
CAS: 1015474-32-4 F: C14H14N4O3 W: 286.29
Avadomide (CC 122) is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity andinduces ap
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.